A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
authorize the use of emergency use authorization data 
and real world evidence gathered during an emergency 
to support premarket applications for drugs, biological 
products, and devices, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘FDA Advancing Col-
4
lection of Transformative Science Act’’ or the ‘‘FACTS 
5
Act’’. 
6
03:36 Jul 28, 2021
H4511
2 
•HR 4511 IH
SEC. 2. USING EMERGENCY USE AUTHORIZATION DATA 
1
AND REAL WORLD EVIDENCE GATHERED 
2
DURING AN EMERGENCY TO SUPPORT PRE-
3
MARKET APPLICATIONS FOR DRUGS, BIO-
4
LOGICAL PRODUCTS, AND DEVICES. 
5
Section 564(k) of the Federal Food, Drug, and Cos-
6
metic Act (21 U.S.C. 360bbb–3(k)) is amended— 
7
(1) by striking ‘‘If a product’’ and inserting the 
8
following: 
9
‘‘(1) IN GENERAL.—If a product’’; and 
10
(2) by adding at the end the following: 
11
‘‘(2) DATA RELATING TO A DRUG, BIOLOGICAL 
12
PRODUCT, OR DEVICE GENERATED DURING EMER-
13
GENCY USE.—Emergency use-related data submitted 
14
by a sponsor in an application for, or submission re-
15
lating to, the approval, licensure, or clearance of a 
16
drug, biological product, or device may constitute 
17
valid scientific evidence or otherwise satisfy the 
18
standard of evidence for approval, licensure, or 
19
clearance of such drug, biological product, or device, 
20
and shall be considered for purposes of— 
21
‘‘(A) reviewing submissions and approving, 
22
licensing, or clearing such drug, biological prod-
23
uct, or device pursuant to, as applicable, sec-
24
tions 505, 510(k), 513(f), and 515 of this Act 
25
03:36 Jul 28, 2021
H4511
3 
•HR 4511 IH
and section 351 of the Public Health Service 
1
Act; and 
2
‘‘(B) otherwise meeting the requirements 
3
of this Act or section 351 of the Public Health 
4
Service Act. 
5
‘‘(3) APPLICABILITY OF CERTAIN CATEGORIZA-
6
TIONS
FOR
PREMARKET
DEVICE
REVIEW.—In the 
7
case of a device receiving an authorization under 
8
this section for which the Secretary has determined, 
9
in accordance with subsection (m), that a laboratory 
10
examination or procedure associated with such de-
11
vice is deemed to be in the category of examinations 
12
and procedures described in section 353(d)(3) of the 
13
Public Health Service Act, such determination shall 
14
apply with regard to a submission pursuant to sec-
15
tion 510(k), 513(f), or 515 for such device, unless 
16
the Secretary (taking into account any applicable 
17
conditions specified pursuant to subsection (m)(2) of 
18
this section) identifies new information not included 
19
in the request for authorization that indicates that 
20
the criteria under section 353(d)(3) of the Public 
21
Health Service Act are not met. 
22
‘‘(4) RULE
OF
CONSTRUCTION.—Nothing in 
23
this subsection shall be construed as altering the re-
24
view standards or otherwise affecting the require-
25
03:36 Jul 28, 2021
H4511
4 
•HR 4511 IH
ments under section 505, 510(k), 513(f), or 515 of 
1
this Act, or section 351 of the Public Health Service 
2
Act for the approval, licensure, or clearance of a 
3
drug, biological product, or device. 
4
‘‘(5) EMERGENCY
USE-RELATED
DATA
DE-
5
FINED.— 
6
‘‘(A) IN GENERAL.—In this subsection, the 
7
term ‘emergency use-related data’ means— 
8
‘‘(i) data that is used to support the 
9
issuance of an authorization under this 
10
section with respect to a drug, biological 
11
product, or device; 
12
‘‘(ii) data generated during the period 
13
under which such authorization is in effect, 
14
with respect to such drug, biological prod-
15
uct, or device; and 
16
‘‘(iii) real world evidence relating to 
17
such drug, biological product, or device 
18
used pursuant to such authorization. 
19
‘‘(B) EXCLUSION.—Such term does not in-
20
clude data previously reviewed and determined 
21
to be inadequate or insufficient to support such 
22
an authorization.’’. 
23
Æ 
03:36 Jul 28, 2021
H4511
